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  There are two long-term objective of this project 1. Is to use a novel I-Domain Antigen 
Conjugate (IDAC) molecule to target antigenic peptide to APC to control autoimmune diseases. 
The short-term objectives of this project are to synthesize, formulate, and evaluate the efficacy of 
Myelin Oligodendrocyte Glycoprotein (MOG) MOG-PEG-IDAC molecules in suppressing 
Experimental Autoimmune Encephalomyelitis (EAE) in animal models. The MOG-PEG-IDAC 
molecule is hypothesized to simultaneously bind to major histocompatibility complex II (MHC-
II) and intercellular adhesion molecule 1 (ICAM-1) on the surface of antigen-presenting cells 
(APC).  2. Is to evaluate the efficacy of PLP-PEG-B7AP in suppressing EAE in mice.  The PLP-
PEG-B7AP molecule is hypothesized to simultaneously bind to the MHC-II and B7 molecule on 
the surface of the APC. This binding blocks the formation of the “immunological synapse” and 
will generate the regulatory response to suppress EAE. Two specific aims are proposed to carry 
out the short-term objectives.  The first specific aim is to design MOG-PEG-IDAC molecules.  
The second specific aim is to evaluate the efficacy of PLP-PEG-B7AP in suppressing EAE in 
animal models.  To date, the synthesis and characterization of the MOG-PEG-IDAC has been 
completed, along with EAE animal studies of the PLP-PEG-B7AP. 
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Chapter 1 
Synthesis, Formulation, and In vivo Evaluation of MOG-PEG-IDAC and PLP-PEG-B7AP 
for Targeting APC to Suppress EAE 
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The long-term goal of this project is to develop therapeutic molecules to treat autoimmune 
diseases such as multiple sclerosis (MS), type-1 diabetes, and rheumatoid arthritis in an antigen-
specific manner without suppressing the general immune response. The short-term goals of this 
project are to synthesize I-domain antigenic-peptide conjugate (IDAC) molecules and 
bifunctional peptide inhibitor (BPI) molecules with MOG and PLP peptides and evaluate their in 
vivo efficacy to suppress EAE in the animal model. To accomplish our short-term goals, we 
carried out two different Specific Aims: 
Specific Aim 1:  To synthesize and characterize MOG-IDAC and MOG-PEG-IDAC for their 
efficacy evaluation in MOG-stimulated EAE in mice. This work is described in Chapter 2. 
Specific Aim 2:  To synthesize PLP-PEG-B7AP molecule and evaluate its efficacy as a 
“therapeutic vaccine” in the EAE animal model. This work is described in Chapter 3. 
MS is a neurological autoimmune disease in which the activated T-cells recognize self-
proteins of the myelin sheath as antigens. As a result, an inflammatory response is initiated 
within the central nervous system (CNS) to demyelinate the axons of nerve cells.  Experimental 
autoimmune encephalomyelitis (EAE) is an animal model that has been used to evaluate 
therapeutic agents for treating MS. This animal model has disease characteristics similar to those 
of MS.  For example, antigenic proteins such as myelin basic protein (MBP), proteolipid protein 
(PLP), and myelin oligodendrocyte glycoprotein (MOG) that elicit the autoimmune response are 
similar in both MS and EAE. Current therapies for MS that focus on suppressing the general 
immune response lack specificity and leave the patient susceptible to infection.  The objective of 
this project is to develop conjugates of antigenic peptides that target the antigen-presenting cells 
(APC) for modulating subpopulations of T cells from inflammatory phenotype to 
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regulatory/suppressor phenotype. To accomplish this objective, our group synthesized and 
evaluated the efficacy of bi-functional peptide inhibitors (BPI) and I-domain antigenic-peptide 
conjugates (IDAC). These molecules are designed to simultaneously target the major 
histocompatibility complex II (MHC II) and adhesion receptors on APC to inhibit the 
immunological synapse formation and prevent the activation of T cells. 
Our previous data showed that PLP-IDAC can significantly suppress PLP-induced EAE in 
mice when administered in prophylactic and vaccine-like manners. PLP-IDAC decreases the 
production of inflammatory cytokines (e.g., IL-17) and increases the production of regulatory 
cytokines (e.g., IL-10), suggesting a shift in T-cell proliferation from an inflammatory to a 
regulatory phenotype.  An IDAC molecule contains multiple antigenic peptides ranging from 4 
to 8; this property provides a unique opportunity for simultaneously delivering multiple antigenic 
peptides from PLP, MOG, and MBP to prevent antigenic spreading in MS. However, in carrying 
out the evaluation of a multiantigen IDAC molecule, we have to demonstrate that an IDAC 
molecule with another antigen such as MOG or MBP peptides (i.e., MOG-IDAC or MBP-IDAC) 
could also suppress EAE effectively.  In this study, MOG peptide (i.e., MOG-Cys) was 
conjugated to the I-domain to make MOG-IDAC and MOG-PEG-IDAC. The synthesis of MOG-
IDAC was inefficient, and the amount of product could only be used for chemical and physical 
characterization; there was  not a sufficient amount to carry out animal studies. This inefficiency 
was due to the insolubility of the MOG-Cys peptide. Therefore, MOG-Cys peptide was modified 
to MOG-PEG-Cys peptide with polyethylene glycol groups in between the MOG peptide 
sequence and the Cys residue. Conjugation of MOG-PEG-Cys and the I-domain successfully 
produced MOG-PEG-IDAC. The purpose of the second chapter is to describe the synthesis and 
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characterization of MOG-IDAC and MOG-PEG-IDAC molecules. The efficacy study of this 
MOG-PEG-IDAC is still ongoing. 
In our earlier work, a novel PLP-B7AP molecule was found to effectively suppress PLP-
stimulated EAE in mice upon administration of the peptide as a prophylactic; different from 
PLP-BPI with LABL peptide, this molecule contains another costimulatory peptide derived from 
the CD28 sequence that binds to B7 receptors. However, the PLP-B7AP molecule has not been 
evaluated in vaccine-like treatment of EAE in the mouse model.  In the third chapter, we 
designed PLP-PEG-B7AP to improve solubility and evaluate its efficacy as a vaccine-like 
treatment to suppress EAE. PLP-PEG-B7AP has a polyethylene glycol group as a linker. MOG-
PEG-B7AP was also synthesized, and the efficacy of MOG-PEG-B7AP is being investigated in 
MOG-stimulated EAE. 
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2.1. Introduction 
The damage in myelin sheaths around the nerve axons is one of the pathogenesis of multiple 
sclerosis (MS) where nerve signal transmission is slowed down or completely disrupted [1]. 
Therefore, MS is characterized as neurological autoimmune disease that is signified by 
inflammation and demyelination of the central nervous system (CNS) due to the presence of  
autoreactive T-cells in the CNS [2]. The permanent loss of protective myelin sheath of the nerve 
axons leads to irreversible neurological dysfunction in chronic MS patients [1]. Up to now, the 
triggers that cause MS in patients have not been elucidated; however, several different 
pathogeneses of the disease have been proposed, including patient’s multiple exposure to 
Epstein-Barr virus infections, environmental factors, stressful life events, and genetic inheritance 
[3-7]. Much like other autoimmune diseases (e.g., rheumatoid arthritis (RA) and type-1 
diabetes), MS pathogenesis involves autoreactive T and B cells that are stimulated during 
inflammatory immune response to produce the disease onset and progression [8, 9].   
There are several therapeutic agents currently used to treat MS as well as in clinical trials, 
including Fingolimod (FTY720), Natalizumab (Tysabri
®
), IFNB-1b (Betaseron
®
), Mitoxantrone 
(Novantrone
®
), and glatiramer acetate (COP1, Copaxone
®
) [10-15]. These treatments have 
varying mechanisms of action but they operate on the premise of suppressing general immune 
responses instead of preventing and stopping the cause of MS.  Therefore, there is a need to 
develop novel therapeutic agents that target and suppress a specific sub-population of immune 
cells that are involved in generating the disease without suppressing the general immune 
responses. 
To find a new way to treat MS, our group has recently developed a novel way to suppress the 
activation of a selected sub-population of immune cells such as inflammatory T cells (i.e., Th-17 
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and Th-1) and to induce the proliferation of regulatory T cells (T-reg). This new method uses bi-
functional peptide inhibitor (BPI) molecules that consist of a cell adhesion peptide linked to an 
antigenic peptide to target the antigenic peptide to antigen-presenting cells (APC) for altering the 
differentiation and proliferation of naïve T cells to regulatory/suppressor T cells (T-reg and Th2) 
for suppressing the disease [16].  
Our previous studies have shown that BPI molecules suppressed autoimmune diseases in 
animal models for rheumatoid arthritis, type-1 diabetes (T1D) [17] and MS [2, 8, 18-22]. BPI 
molecules have been shown to effectively suppress experimental autoimmune encephalomyelitis 
(EAE) in the mouse model. In this case, BPI molecules were designed by conjugating antigenic 
peptides from myelin sheath proteins such as proteolipid protein (PLP), myelin oligodendrocyte 
protein (MOG), and myelin basic protein (MBP). Although Myelin sheath proteins are 
considered autoantigens recognized by T cells in the development of MS [23], injections of 
soluble form of peptides from the epitopes of these “autoantigens” can suppress EAE in mice [2, 
24].  Interestingly, BPI molecules are more effective than autoantigen peptide alone. The 
proposed mechanism of action of BPI molecules is that they bind simultaneously to the major 
histocompatibility complex class II (MHC-II) and ICAM-1 on the APC and block the 
immunological synapse formation at the APC-T-cell interface. This event causes a shift of T-cell 
differentiation from inflammatory to regulatory phenotypes [2, 17, 20, 21]. The study has now 
been extended to evaluate the efficacy of MOG-BPI, which is a conjugate between MOG(38-50) 
and LABL (CD11a237-246) peptides; MOG-BPI has been shown to be more effective than 
MOG(38-50) peptide in suppressing of MOG-induced EAE in the mouse model [18]. 
Previously, multiple PLP(139-151) peptides were conjugated to the lysine residues of the I-
domain of LFA-1 protein to make I-domain antigen conjugates (IDAC) molecules (i.e., PLP-
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IDAC) and PLP-IDAC can effectively suppress EAE in the animal model presumably by 
blocking both signal-1 and signal-2 of the immunological synapse [25, 26]. IDAC molecules 
have an advantage of delivering multiple antigens due to multiple conjugations of antigen to the 
I-domain protein[25].  In this study, we explored the possibility of conjugating several MOG(38-
50) peptides to the I-domain to make MOG-IDAC or MOG-PEG-IDAC molecules for potential 
evaluation of their efficacies in MOG-stimulated EAE. Thus, the MOG-IDAC and MOG-PEG-
IDAC were synthesized by conjugating the multiple MOG-Cys and MOG-PEG-Cys to gamma-
maleimido-butyramide (GMB) groups on the lysine residues of the I-domain protein. The 
resulting MOG-IDAC or MOG-PEG-IDAC was purified using size exclusion chromatography 
and characterized using SDS-PAGE, mass spectrometry and circular dichroism (CD) 
spectroscopy. 
 
2.2 Experimental Procedures 
2.2.1. Materials. Amino acids used in peptide synthesis were purchased from Peptide 
International Inc. (Louisville, KY). GMBS (N-[γ-maleimidobutryloxy]succinimide ester) was 
purchased from Pierce Inc. (Rockford, IL).  All other chemicals and solvents used were of 
analytical grade. 
 
2.2.2 Peptide Synthesis. The MOG-Cys (Ac-GWYRSPFSRVVHLC-NH2) and MOG-PEG-
Cys (Ac-GWYRSPFSRVVHL-Peg-Peg-C-NH2) peptides were synthesized with automated 
peptide synthesizer (Pioneer; Perceptive Biosystems, Framingham, MA) using Fmoc chemistry 
as previously described (see reference [2]). A list of peptides used can be found in table 2.1. 
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After peptide cleavage from the resin using trifluoroacetic acid (TFA), the crude peptides were 
purified by reversed-phase high performance liquid chromatography (HPLC) on a semi-
preparative C18 column with a gradient of solvent A (94.9% H2O, 5% Acetonitrile, 0.1% TFA) 
and solvent B (100% acetonitrile). Analytical HPLC was used to determine the purity of each 
peptide fraction collected from a semi-preparative HPLC. Fractions that showed high purity were 
then pooled together and lyophilized. ESI mass spectrometry indicated that the pure MOG-Cys 
(M+H = 1748.075) and MOG-PEG-Cys (M+H = 2126.39) have the correct molecular weights. 
 
Peptide Sequence Molecular 
Weight 
MOG-Cys Ac-GWYRSPFSRVVHLC-NH2 1748.075 
MOG-PEG-
Cys 
Ac-GWYRSPFSRVVHL-PEG-PEG-C-NH2 2126.39 
 
Table 2.1.  Peptides used in current study.  Peptides sequences of both MOG-Cys and MOG-
PEG-cys peptides. 
 
2.2.3 Preparation of the I-domain. The I-domain protein was previously overexpressed, 
refolded, and purified using methods described in earlier work [27].  The purity and structural 
properties of the I-domain protein were evaluated by mass spectrometry, SDS-PAGE, and CD. 
2.2.4. Synthesis of MOG-IDAC and MOG-PEG-IDAC.  The MOG-IDAC and MOG-
PEG-IDAC were synthesized via the formation GMB-I-domain, which was synthesized by 
reacting several lysine residues with N-[γ-maleimidobutyryloxy]-succinimide ester (GMBS) 
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(Figure 2.1). In this case, the I-domain protein (20 mg) was dissolved in 10 ml of buffer (2 
mg/ml) followed by drop-wise addition of 10 fold molar excess of GMBS in 500 μl of DMSO. 
The mixture was stirred for 1 h at 24°C in the absence of light and the crude GMB-I-domain was 
purified using a Superdex 75 size exclusion chromatography (SEC) column in PBS containing 
10 mM MgSO4. After combining all SEC fractions containing GMB-I-domain, the solution was 
concentrated using ultrafiltration.  The number of GMB group per I-domain molecules was 
determined by MALDI-TOF mass spectrometry. 
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Figure 2.1. The reaction steps to make MOG-IDAC or MOG-PEG-IDAC. The first step is 
to derivatize the lysine residues on the I-domain to gamma-maleimido-butyramide (GMB) 
groups. Then in step 2, the maleimide groups are reacted with the thiol group of the cysteine 
residue on the MOG peptide to produce the desired conjugates. 
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To complete the synthesis of MOG-IDAC or MOG-PEG-IDAC, the maleimide groups on the 
GMB-I-domain were reacted with the thiol group of MOG-Cys or MOG-PEG-Cys. In this 
reaction, 15 fold molar excess of the peptide (MOG-Cys or MOG-PEG-Cys) was added drop-
wise into a solution of GMB-I-domain (2.0 mg/ml) at pH 7.5; then, the reaction was carried out 
for 1 hour at 24°C with constant stirring under dark conditions. The resulting MOG-IDAC or 
MOG-PEG-IDAC was purified on a Superdex 75 size exclusion column and eluted with PBS 
containing 10 mM MgSO4. The fractions containing the MOG-IDAC or MOG-PEG-IDAC were 
collected and concentrated by ultrafiltration and the number of peptides conjugated to the I-
domain was determined by MALDI-TOF mass spectrometry.  The purity of the IDAC molecules 
was confirmed by SDS-PAGE gel and size-exclusion chromatography.  The secondary structure 
was confirmed by far-UV CD and compared to the parent GMB-I-domain and I-domain. 
 
2.2.5. Gel Electrophoresis. The purity of protein solution of I-domain, GMB-I-domain, 
MOG-IDAC, MOG-PEG-IDAC obtained from SEC separation was analyzed by SDS-PAGE. 
Approximately 100 μg of protein in solution was mixed with 4x Tris-glycine SDS sample buffer 
without reducing agent and loaded into 1.5 mm thick 10 well NuPAGE Novex 4–12% Bis-Tris 
gradient gel.  The gel was run for 1 h at 150 V, then was stained with 0.25% coomassie blue 
R250 solution (10% acetic acid, 50% ethanol, 40% water) for 30 min followed by destaining 
(10% acetic acid, 25% ethanol, 65% water) until the bands were visible and the background was 
completely clear.  
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Figure 2.2. SEC Chromatogram of GMB-I-Domain.  SEC chromatogram showing the 
separation between GMB-I-domain and unreacted GMBS. The crude reaction of reaction 
between GMBS and I-domain was purified using Superdex 75 column eluted with PBS with 10 
mM MgSO4.  
  
GMB-I-domain 
Unreacted GMBS 
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Figure 2.3. MALDI-TOF mass spectrum of GMB-I-domain protein. The conjugates 
contain 5 to 10 GMB groups per I-domain molecule.  
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2.3. Results 
2.3.1. Conjugation of GMBS to I-domain. The formation of GMB-I-domain was very 
efficient and it can readily be separated from the unreacted GMBS using SEC (Figure 2.2). The 
pure GMB-I-domain has 5 to 10 GMB groups attached per I-domain molecule as determined by 
MALDI-TOF mass spectrometry (Figure 2.3). The parent I-domain with a molecular weight of 
20,682 Da (previous data) [25] was not observed in the MS spectra of the GMB-I-domain 
conjugates. The mass spectrometry demonstrated multiple conjugates of GMB to I-domain 
protein with molecular weights of 21,526 Da, 21,691 Da, 21,856 Da, 22,020 Da, 22,185 Da, 
22,351 Da with a difference of 165 Da for a GMB group (Figure 2.3). The first peak with 21,526 
Da was from GMB-I-domain with 5 GMB groups; thus, the remaining peaks correspond to 
GMB-I-domain with 6 to 10 GMB groups, respectively. The mass spectrum of GMB-I-domain 
also produced peaks with corresponding peaks of 18 Da mass increased (Figure 2.3), which were 
due to the hydrolysis of the attached maleimide groups. These results are consistent with the SDS 
PAGE gel that indicates two bands of the desired maleimide conjugate and maleic acid 
derivatives, which have different electrophoretic mobility (Figure 2.4, lane 3).  In the case of the 
parent I-domain, only one band appears on the gel (Figure 2.4, lane 2). The formation of 
hydrolysis products from the GMB-I-domain increases upon storage, so it is necessary that the 
GMB-I-domain be used for the next conjugation reaction within 48 hours of SEC purification. In 
order to better understand the structure of the GMB-I-domain conjugate the secondary structure 
of GMB-I-domain was compared to the I-domain using CD spectroscopy (Figure 2.5) and both 
molecules have similar secondary structure. 
16 
 
 
Figure 2.4.    SDS-PAGE of GMB-I-Domain. SDS-PAGE analysis of pure GMB-I-domain 
compared to the I-domain protein after SEC purification. The gel was stained with staining 
coomassie blue: lane 1 for marker molecules, lane 2, for I-domain, and lane 3 for GMB-I-
domain. 
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Figure 2.5.   CD Spectra of GMB-I-Domain. GMB-I-domain (Blue) has similar CD spectrum   
with the parent I-domain (Red). 
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2.3.2. Synthesis of MOG-IDAC.  MOG-IDAC was synthesized by conjugating MOG-Cys 
to  the GMB-I-domain at pH 7.5 using previously described method [25]. MOG-Cys is the 
MOG(38-50) peptide with an additional cysteine amino acid at the C-terminus and the peptide was 
also amidated and acetylated at the N- and C-terminus. The peptide conjugation is via 
nucleophilic attack on the maleimide groups of the GMB-I-domain by the thiol group of the Cys 
residue on MOG-Cys (Step 2, Figure 2.1). The crude sample of the MOG-IDAC was analyzed 
by SDS-PAGE against the parent I-domain and GMB-I-domain (Figure 2.6). The gel of the 
crude product of MOG-IDAC (lane 6, Figure 2.6) shows multiple bands at around 20 kDa, 
indicating the protein is a mixture of conjugates different amount of conjugated peptides. Lane 6 
also illustrates the presence of a lower MW bands corresponding to excess MOG-Cys peptide. 
The parent I-domain (lane 2) shows one single band with lower molecular weight than GMB-I-
domain (lane 4) and MOG-IDAC (lane 6).  
The reaction mixture was purified through SEC and the eluted fractions of desired pure 
MOG-IDAC were pooled and concentrated. Unlike the SDS-PAGE of the crude product, the  
pure fraction shows a single peak at the desired product without the presence of MOG-Cys 
peptide peak (Figure 2.7). The pure product was subjected to MALDI-TOF MS analysis and 
multiple peaks were observed to indicate 1 to 2 of MOG-Cys peptides conjugated to a molecule 
of I-domain (Figure 2.8). Finally, the CD spectrum of MOG-IDAC was compared to GMB-I-
domain and parent I-domain (Figure 2.9) and the results confirm that MOG-IDAC has similar 
secondary structure with GMB-I-domain and I-domain. 
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Figure 2.6. The SDS-PAGE of the crude reaction to make MOG-IDAC. Compared to 
GMB-I-domain (lane 4) and I-domain (lane 2). In lane 6, the MOG-IDAC shows multiple 
products around 20 kDa with different number of conjugated peptides. The crude also shows 
peptide band at a low molecular weight. 
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Figure 2.7. SEC Chromatogram of MOG-IDAC. Analytical SEC chromatogram of MOG-
IDAC after purification using Superdex 75 column eluted with PBS with 10 mM MgSO4. The 
chromatogram did not show any peak for the left over MOG-Cys peptide. 
  
 
   -     
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Figure 2.8. Mass spectra of MOG-IDAC. MALDI-TOF mass spectrum of MOG-IDAC 
conjugates with one or two peptides per molecule I-domain. 
  
+2    +1    
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Figure 2.9. CD Spectra of MOG-IDAC.  Comparison of CD spectra of parent I-domain 
(Blue), GMB-I-domain (Red), and MOG-IDAC (Green). The spectrum of MOG-IDAC was not 
dramatically altered upon peptide conjugation, suggesting that the I-domain in the conjugate 
maintains its secondary structure. 
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2.3.3. Synthesis of MOG-PEG-IDAC. The problem in synthesizing MOG-IDAC molecule 
is that the MOG peptide was insoluble limiting the conjugation efficiency. In an attempt to 
increase the solubility of the peptide, two poly-ethylene glycol amino acids (i.e., 11-amino-3,6,9-
trioxaundecanoic acid) (Figure 2.10)  were inserted between the C-terminus of the MOG peptide 
and the cysteine C-terminal amino acid to give MOG-PEG-Cys peptide. Conjugation of the 
MOG-PEG-Cys to GMB-I-Domain was completed in the same manner as MOG-IDAC; the 
reaction yielded the MOG-PEG-IDAC conjugate. The molecule was purified with SEC (Figure 
2.11) and SDS-PAGE of the pure product of MOG-PEG-IDAC shows a broad band similar to 
that of MOG-IDAC (Figure 2.12). The number of conjugated peptide was determined by 
MALDI-TOF MS (Figure 2.13) and there are 1 to 2 conjugated peptide per one molecule of I-
domain. CD spectral analysis was carried out to compare the secondary structure of MOG-PEG-
IDAC to MOG-IDAC, GMB-I-domain and I-domain (Figure 2.14). There is a change in the 
secondary structure of MOG-PEG-IDAC compared to that of MOG-IDAC.  
 
 
 
 
 
 
 
 
 
 
 
24 
 
 
 
Figure 2.10.  Peg linker for MOG-PEG-IDAC.  Fmoc-11-amino-3,6,9-trioxaundecanoic 
acid is the pegylated amino acid used in the synthesis of MOG-PEG-IDAC with a molecular 
weight of 429.47. 
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Figure 2.11. SEC Chromatogram of MOG-PEG-IDAC.  The SEC chromatogram of MOG-
PEG-IDAC appears in a single peak of the conjugate; however, conjugation still yields some 
protein precipitation. Thus, the amount of protein is solution is low and causes a low absorbance 
reading of MOG-PEG-IDAC in UV detection during SEC. 
  
   -PE -     
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Figure 2.12. SDS PAGE of MOG-PEG-IDAC.  Shows a broad band of the desired product 
without the presence of precursor MOG-PEG-Cys peptide. 
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Figure 2.13. Mass Spectrum of MOG-PEG-IDAC.  The mass spectrum of MOG-PEG-IDAC 
to indicate that there are one to two peptides conjugated to the I-domain. 
 
+1 MOG 
+2 MOG 
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Figure 2.14. CD Spectra of MOG-PEG-IDAC.  CD spectra of parent I domain (Blue), GMB-
I-Domain (Red), MOG-IDAC (Green), MOG-PEG-IDAC (Purple). The is a significant change in 
the CD spectrum of MOG-PEG-IDAC, suggesting there is alteration of the secondary structure 
of the conjugate. 
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2.4. Discussion 
Today, patients with autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, 
and psoriasis are currently being treated with protein derived drugs such as peptide and 
monoclonal antibodies to modulate their immune systems.  Multiple sclerosis patients are 
currently being treated with Copaxone® and Tysabri®, along with other anti-inflammatory 
agents (e.g., mitoxantrone, and Beta-interferon 1a).  One common monoclonal antibody 
treatment is Tysabri, which binds to the α4 subunit of the α4β1 and α4β7 integrins on the surface 
of leukocytes. 
Blocking of the α4 subunit prevents leukocyte adhesion to endothelial cells and subsequent 
infiltration of T cells and other immune cells into the CNS.  Unfortunately, some patients treated  
with Tysabri have develop progressive multifocal leukoencephalopathy (PML) conditions, a life 
threatening complication with no available cure [14]. A monoclonal antibody, Raptiva 
(Efalizumab, CD11a mAB) for cell adhesion molecules has been used to treat psoriasis but due 
to PML complications, this drug was withdrawn from the U.S. market [28, 29].  In addition to 
blocking T-cell adhesion to endothelial cells, Tysabri and Raptiva can also block signal-2 
recognition between the APC and T-cell. As a result, it may cause a general suppression of T-cell 
activation and prevents T-cells from responding to pathogens like JC virus which is responsible 
for the appearance of PML. With this knowledge, there is a need to develop a new therapy that 
does not suppress the general immune response but is more specific to regulating a  certain 
population of immune cells. 
To generate a more antigen-specific immune suppression, our group has developed the BPI 
molecules such as PLP-BPI, GAD-BPI, and CII-BPI that suppress MS, type 1 diabetes, and 
30 
 
rheumatoid arthritis in animal models [2, 17, 20-22]. In conjunction with the BPI molecules, 
PLP-IDAC molecules were also developed with several antigenic PLP peptides to a single I-
domain [25]. Following induction with one antigen, the disease could exacerbate to include 
multiple antigens and this phenomenon is termed “antigenic spreading” [30]. The hope is that 
IDAC can deliver multiple and different antigenic peptides from different myelin sheath proteins 
(i.e., PLP, MOG, and MBP) for preventing antigenic spreading in autoimmune diseases. Thus, it 
may provide a unique approach to treating MS. Another advantage is that both BPI and IDAC 
molecules has been shown to suppress the disease when administered as “vaccine like” 
treatments; in this case, the molecules are delivered several days before induction of the disease 
[25]. The proposed mechanism of action of PLP-IDAC molecules is similar to that of BPI 
molecule in which they inhibit the formation of the immunological synapse by simultaneous 
binding to ICAM-1 and MHC-II on the surface of APC. This inhibition prevents the activation of 
T cell and/or alters the differentiation of inflammatory to regulatory T cells. 
 Although MOG-IDAC was successfully produced, the production yield was very low and 
was not sufficient quantity for animal studies. However, the amount was sufficient to 
characterized the molecules by SDS-PAGE, mass spectrometry, and CD spectroscopy [25].  The 
difficulty of producing MOG-IDAC was due to the insolubility of MOG-Cys peptide to make the 
reaction with GMB-I-domain inefficient. In this case, MOG-Cys peptide had to be dissolved in 
DMSO before adding to the reaction mixture for conjugation. This conjugation reaction was less 
efficient than conjugation between PLP-Cys and GMB-I-domain to make PLP-IDAC. Different 
reaction conditions were explored including changing the pH and buffers to improve the 
efficiency of the reaction; unfortunately, none of the change resulted in improved reaction 
efficiency to make MOG-IDAC. The best reaction condition was by adding the dissolved MOG 
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peptide in DMSO drop wise to the GMB-I-domain reaction mixture.  At pH 7.4, the reaction 
mixture still produces slight cloudiness in the solution; however, upon filtration, the filtrate 
showed successful conjugation in SEC. This inefficiency was also reflected by the low number 
of peptide conjugated to the I-domain in MOG-IDAC compared to PLP-IDAC. It should be 
noted that the PLP-IDAC has a maximum of five peptides per-molecule of I-domain. It is 
interesting to find that adding MOG peptides did not dramatically alter the CD spectra MOG-
IDAC compared to the I-domain, suggesting that the MOG peptide has low contribution to the 
secondary structure of the conjugates. Due to the difficulty of producing sufficient quantity, the 
animal studies were not carried out with MOG-IDAC. 
To improve the synthesis of the conjugate, solubility of the peptide was improved by adding 
PEG groups between MOG peptide and the cysteine residue to make MOG-PEG-Cys. It has 
been shown that PEGylation of proteins and peptides improves the biopharmaceutical properties, 
through increase in solubility, increase in half-life, and decrease in immunogenicity [31, 32].  
PEGylation has been shown to be safe and non-toxic. For example, certolizumab pegol is a 
TNFα antibody; this molecule is a humanized Fab’ antibody fragment conjugated to PEG to 
increase the half-life and decrease immunogenicity [33]. This drug has been used in the clinic for 
the treatment of RA. Our group had also utilized PEG group as a linker to make PLP-PEG-BPI 
and the use of PEG in PLP-PEG-BPI lowered the anaphylaxis incidence compared to PLP-BPI 
molecules in the EAE mouse model [21]. Besides increasing solubility, the hope is that adding 
PEG groups as a linker could also lower the toxicity profile (i.e., anaphylaxis reaction) of MOG-
PEG-IDAC [25]. Unfortunately, the solubility of MOG-PEG-IDAC was still not improved 
tremendously compared to MOG-IDAC because precipitation was still observed during 
conjugation reaction at neutral pH. The secondary structure of MOG-PEG-IDAC was also 
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altered to increase the beta-sheet structure compared to the MOG-IDAC and the I-domain as 
shown in the CD spectra (Figure 2.13). The beta-sheet structure in the MOG-PEG-IDAC may 
lead to aggregation of the conjugate, contributing to the insolubility of the MOG-PEG-IDAC. It 
is not clear whether the increase in beta sheet structure is due to the contribution of the MOG 
peptide to the secondary structure of the conjugate or it is due to the change of random coil or 
alpha helix structure to beta sheet within the I-domain protein of the conjugate. In the future, 
further studies will be carried out to evaluate the effect of MOG peptide on the secondary 
structure of the IDAC.  
In conclusion, we have developed a new IDAC molecule (MOG-IDAC and MOG-PEG-
IDAC) and successfully managed to purify and characterize it using SEC, SDS-PAGE, Mass 
Spectrometry, and CD. In the future, there will be a need to improve the efficiency of the 
conjugation reaction in order to progress to proof-of-concept of the MOG-PEG-IDAC in EAE 
animal models for suppression of disease. The efficacy of MOG-PEG-IDAC in suppressing EAE 
is currently being studies in the MOG-stimulated EAE in C57BL/6 mice. The effect of the 
conjugate in altering the cytokine production will also be determined. Furthermore, the physical, 
chemical, and plasma stability of the conjugates will be investigated in the future. 
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Chapter 3 
Suppression of EAE using vaccine-like treatment with PLP-PEG-B7AP 
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3.1. Introduction 
Multiple sclerosis (MS), an autoimmune neurological disease,  is difficult to treat because it 
involves the destruction of the myelin sheath of the axon connecting the nerve cells in the central 
nervous system (CNS) [1, 2].  In the disease pathogenesis, the immune cells recognize the major 
self-proteins on the myelin sheath, including proteolipid protein (PLP), myelin oligodendrocyte 
glycoprotein (MOG), and myelin basic protein (MBP) [3].  For T-cell activation and modulation, 
TCR/MHC-II-Ag complex (Signal-1) and costimulatory signal (Signal-2) are generally required 
during the interaction between T cells and antigen-presenting cells (APC) [4].  The positive 
costimulatory signals can be delivered by CD28/B7 interactions (B7 on APC and CD28 on T 
cells) [5, 6].  In contrast, the negative costimulatory signal can be delivered by B7/CTLA-4 [7]. 
The CD28 protein on CD4+ T cells binds to the B7.1 and B7.2 receptors on APC via a 
conserved region with MYPPPY sequence [8, 9].  B7AP peptide containing the conserved 
MYPPPY sequence can bind to B7 receptors and block CD28/B7 interactions without affecting 
the B7/CTLA-4 interactions [10].  Blocking C28/B7 interactions with B7AP peptide has been 
shown to prevent rejection of organ transplants in an animal model [10]. Another peptide called 
EL-CD28 that has the MYPPPY sequence was also shown to suppress experimental autoimmune 
encephalomyelitis (EAE) in an animal model [6]. It has been proposed that blocking the specific 
binding of the MYPPPY region of CD28 to both B7.1 and B7.2 receptors can induce T-cell 
anergy for suppression of the immune response [11-14].  In the animal studies, administration of 
anti-B7.1 antibody that recognizes the binding site of MYPPPY sequence of CD 28 can induce 
exacerbation of diabetes in non-obese diabetic mice, suggesting that CD28/B7 costimulatory 
interaction is important for inducing T-cell activation.  [11].  
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Interactions between cell adhesion molecules such as intercellular adhesion molecule-1 
(ICAM-1) and leukocyte function-associated antigen-1 (LFA-1) play an important role in the 
formation of the immunological synapse for T-cell activation [15, 16]. Our previous findings 
show that novel bifunctional peptide inhibitor (BPI) molecules that are a conjugate between 
antigenic peptide(s) and cell adhesion peptide(s) from the ICAM-1 or LFA-1 sequence can 
effectively suppress EAE in the mouse model [2, 17, 18].  The proposed mechanism of BPI 
molecules is that they block immunological synapse formation and stop the activation of a 
specific population of immune cells; therefore, they avoid the general suppression of immune 
cells [2, 18]. It is believed that this type of treatment has an advantage over treatments with drugs 
that suppress the general immune response. Recently, another type of BPI molecule called PLP-
B7AP was developed with B7AP peptide from the sequence of costimulatory signal CD28.  In 
this case, PLP-B7AP is hypothesized to block signal-1 (MHC-II/TCR) and signal-2 (CD28/B7) 
and prevent PLP-specific T-cell activation. A very effective suppression of EAE was achieved 
using PLP-B7AP in treatment on days 4, 7, and 10 following induction of disease at day 0. 
The EAE animal model has been used to better understand the pathogenesis of MS and to 
develop new strategies for the treatment of MS. The pathogenesis EAE model is similar to MS in 
that it is characterized by inflammation of the CNS, breakdown of the blood-brain barrier (BBB), 
and differentiation and proliferation of the TH17 and TH1 cells [15].  To prevent the disease, the 
pro-inflammatory and inflammatory T cells must be suppressed and/or regulated by increasing 
the differentiation and proliferation of regulatory cells (Treg) [19] and suppressor type-2 helper T 
cells (TH2) [20]. Leakiness of the BBB increases in EAE as well as in MS, allowing trafficking 
of leukocytes into the CNS and the subsequent destruction of myelin sheaths [21-23]. Our 
previous studies have demonstrated that the BPI molecule administered in a “vaccine-like” 
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manner can suppress EAE in mice and prevent BBB breakdown as analyzed by magnetic 
resonance imaging (MRI) [24]. 
In this study, a derivative of the PLP-B7AP molecule called PLP-PEG-B7AP was 
synthesized by conjugating PLP139-151 peptide to the B7AP peptide from CD28 via a pegylated 
amino acid linker.  PLP-PEG-B7AP is hypothesized to block the interactions of the primary 
MHC-II/TCR signal and secondary CD28/B7) signal to prevent activation of T cells followed by 
suppression of EAE progression in the animal model. This also demonstrates the importance of 
the CD28/B7 costimulatory signal in the activation of T-cells during autoimmunity.  PLP-PEG-
B7AP was injected subcutaneously (s.c.) in a vaccine-like manner, and disease scores, changes 
in body weight, and incidence of disease were monitored. Cytokine levels produced by 
splenocytes on days 15 and 30 were monitored and analyzed to determine the populations of T 
cells that are proliferating during progression of the disease. Brain samples of mice from days 15 
and 30 were analyzed for leukocyte infiltrations (i.e., CD3+ T cells) and amount of 
demyelination of the CNS. 
 
3.2. Experimental Procedures 
3.2.1. Mice. The University of Kansas  Institutional Animal Care and Use Committee 
(IACUC) approved all protocols for animal experiments using SJL/J(H-2
s
) mice (Charles River, 
Wilmington, MA). The Animal Care Unit facility at The University of Kansas housed the mice 
under the supervision of veterinarians; the facility is approved by the Association for Assessment 
and Accreditation of Laboratory Animal Care. 
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3.2.2. Peptide synthesis. The crude peptides such as PLP139-151 (Ac-HSLGKWLGHPDKF-
NH2), PLP-BPI (Ac-HSLGKWLGHPDKF-(Acp-G-Acp-G-Acp)2-ITDEATDSG-NH2), and PLP-
PEG-B7AP (Ac-HSLGKWLGHPDKF-(PEG)3-G-(PEG)3-EFMYPPPYD-NH2) were synthesized 
by Shanghai Mocell Biotech Co., Shanghai, China.  A list of peptides can be found in table 3.1. 
The crude peptides were purified by reversed-phase high performance liquid chromatography 
(RP-HPLC) on a semi-preparative C18 column with a gradient of solvent A (94.5% H2O, 5% 
acetonitrile, 0.1% TFA) and solvent B (100% acetonitrile). The purity of each fraction from 
semi-preparative HPLC was evaluated using analytical RP-HPLC (C18 column) and all pure 
fractions were pooled and subjected to lyophilization. The identity of each purified peptide was 
confirmed by electrospray ionization mass spectrometry. 
 
Peptide Sequence Molecular 
Weight 
PLP Ac-HSLGKWLGHPDKF-NH2 1665.965 
PLP-BPI Ac-HSLGKWLGHPDKF-Acp-G-Acp-G-Acp-Acp-G-Acp-G-
Acp-ITDGEATDSG-NH2 
3416.91 
PLP-PEG-
B7AP 
Ac-HSLGKWLGHPDKF-PEG3-G-PEG3-EFMYPPPYD-NH2 4008.33 
 
Table 3.1 Peptides used.  Listed table of peptides and their sequences used in current study. 
 
3.2.3. Vaccine-like treatment of EAE with peptides. Prior to disease induction, four groups 
of SJL/J female mice (5–7 weeks) received three s.c. injections of either 100 µl of PBS or 100 µl 
(100 nmol/injection/day) of PLP-PEG-B7AP, PLP-BPI, and PLP peptides at 11, 8, and 5 days 
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prior to induction of disease on day 0. On day 0, the mice then were immunized s.c. with 200 µg 
of PLP in a 0.2 ml emulsion that contained equal volumes of PBS and complete Freund’s 
adjuvant (CFA) containing killed mycobacterium tuberculosis strain H37RA at a final 
concentration of  8 mg/ml (Difco, Detroit, MI). 50 µl of PLP/CFA emulsion was administered to 
regions above the shoulder and the flanks (total of 4 sites). In addition, 200 ng of pertussis toxin 
(List Biological Laboratories, Campbell, CA) was delivered intraperitoneally (i.p.) on days 0 and 
2. The disease progression was measured by clinical scores using the following scoring system: 0 
= no clinical symptoms, 1 = limp tail or waddling gait with tail tonicity; 2 = waddling gait with 
limp tail (ataxia); 3 = full paralysis of one limb; 4 = full paralysis of two limbs; 5 = moribund or 
dead.  The body weight of each animal was determined daily. 
 
3.2.4. Cytokine production assay. In vitro cytokine assays were performed following a 
protocol that was described previously [24]. Briefly, spleens were isolated from 3 animals treated 
with PLP-PEG-B7AP and PBS on days 15 (at the highest disease score) and 30 (at remission). 
Splenocytes were harvested by mashing the spleen and running the cells through a cell strainer in 
serum-free RPMI-1640 medium. ACK lysis buffer (Invitrogen, Carlsbad, CA) was use to remove 
the red blood cells. Serum-free RPMI-160 medium (Cellgro, Manassas, VA) was used to wash 
the remaining splenocytes. The cells were placed in each well of a 24-well plate with a density of 
5 × 10
6
 cells/well and primed with PLP (20 µM). After 72 h, the supernatants from each well 
were collected and stored in a –80°C freezer for up to 78 hours until cytokine analysis to 
measure IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, and IFN-γ using a quantitative ELISA-based Q-
Plex assay (Quansys Biosciences, Logan, UT). 
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3.2.5. Brain tissue staining and analysis. Brain tissue was isolated at the same time as the 
isolation of spleens. After isolation, the brain tissue was placed in a cold solution of 4% 
paraformaldehyde for 48 hours at 4°C. The brain tissue was then rinsed 3 times with PBS and 
then stored in 70% ethanol until it was processed into paraffin blocks. Processing of brain tissue 
was completed at the University of Kansas Medical Center by immersing the brain tissue in a 
gradient of ethanol (70–100%), xylene, and then Paraplast X-tra
®
. The brain tissue was then 
placed in cooled paraffin blocks followed by sectioning. Samples were stained for extent of 
leukocyte infiltration (H&E staining), demyelination (Luk Sol Fast staining), and T-cell 
infiltration (CD3+
 
antibody staining). Staining and analysis were done by IHC World, LLC 
(Woodstock, MD). 
 
3.2.6. Statistical analysis. Statistical analysis was done using one-way analysis of variance 
followed by Fisher’s least significance difference to compare the different parameters, including 
EAE clinical scores, changes in body weight, and in vitro cytokine production.  All statistical 
analyses were performed using SigmaPlot software (Systat Software Inc, San Jose, CA). 
 
3.3 Results 
It has been previously shown that PLP-B7AP (unpublished) and PLP-BPI molecules have 
better efficacy in suppressing EAE than does PLP peptide when injected subcutaneously s.c. on 
days 4, 7, and 10 after disease stimulation using a PLP/CFA emulsion on day 0 [25]. In this 
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study, the efficacy of PLP-PEG-B7AP as a vaccine was evaluated for suppressing EAE in the 
mouse model. The PLP-PEG-B7AP peptide was administered via s.c. injections on days –11, –8, 
and –5 prior to stimulation of disease on day 0 with PLP/CFA emulsion. 
 
3.3.1. Suppression of EAE with PLP-PEG-B7AP. Disease progression and severity were 
measured using a standard disease scoring protocol (Figure3.1), in which scores can range from 
0 to 5.  The first evidence of disease was found in PBS- and PLP-treated mice on days 10 and 11. 
The disease became severe between days 13 and 16 with a maximum average disease score on 
day 15 of 2.50  0.274 for PBS-treated and 2.00  0.315 for PLP-treated mice (n = 6 for each 
group). After the disease peaked, all the mice slowly underwent remission. Half of the PLP-BPI-
treated mice showed signs of disease, which resulted in a maximum average disease score of 
1.08  0.153 observed on days 12–14 and 16 (n = 6 for each group). Less than half of the PLP-
PEG-B7AP-treated mice showed signs of disease during the study, which resulted in a maximum 
average disease score of 0.777  0.078 observed on day 13.  The results suggest that PLP-PEG-
B7AP was able to significantly suppress EAE compared to PBS (p< 0.0001), PLP (p< 0.0001) 
and PLP-BPI (p< 0.0001). 
The efficacy of PLP-PEG-B7AP was also evaluated using percent change in body weight of 
the mice during progression of disease. Overall, the change in body weight correlates with 
progression of the disease. PBS-treated mice showed a significant loss in body weight 
(approximately 17%) (p< 0.001)  on day 13 when compared to PLP- (~15%) (p< 0.001), PLP-
BPI- (~10%) (p< 0.001), and PLP-PEG-B7AP-treated mice (~5%) (p< 0.001) (Figure 3.2)  After 
day 13, it was difficult to compare the body weights because two mice from the PBS-treated 
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group and one mouse from the PLP-treated group had to be euthanized due to very high disease 
scores.  A summary of the incidence of disease is shown in Figure 3.3. 
 
 
 
 
 
 
 
 
48 
 
   
Figure 3.1. Disease Scores of PLP-PEG-B7AP treated mice.  In vivo efficacies of 
PLP-PEG-B7AP, PLP-BPI, PLP, and PBS in suppressing EAE upon vaccination with these 
compounds on days –11, –8, and –5 followed by  immunization with PLP/CFA on day 0. PLP-
PEG-B7AP, PLP-BPI, and PLP peptides were administered at a dose of 100 nmol/100 
µl/injection.  EAE disease scores were significantly lower for PLP-PEG-B7AP (p<0.0001) 
treated mice than those of PLP-BPI (p<0.0001), PLP (p<0.0001), and PBS(p<0.0001) treated 
mice. 
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Figure 3.2. Changes in weight of PLP-PEG-B7AP treated Mice. In vivo efficacies 
of PLP-PEG-B7AP, PLP-BPI, PLP, and PBS were investigated by monitoring the changes in 
body weight of the animals. Until day 11, PBS (p<0.001)-treated mice demonstrated a significant 
loss in body weight when compared to PLP (p<0.001), PLP-BPI (p<0.001), and PLP-PEG-
B7AP-treated mice (p<0.001).  Differences between groups are not so apparent on days 12 and 
13, due to the euthanasia of one PLP-treated and two PBS-treated mice. However, the 
differences in change in body weight become apparent again on days 14 and 15, showing 
significant loss in body weight in PBS-treated mice compared to PLP-, PLP-BPI-, and PLP-
PEG-B7AP-treated mice (p<0.0001). 
50 
 
 
Figure 3.3. Incidence of Disease of PLP-PEG-B7AP treated mice.  Disease 
incidence in EAE mice during in vivo efficacy studies of PLP-PEG-B7AP, PLP-BPI, PLP, and 
PBS. To be considered to have an incidence of disease, the mouse must have a disease score of 
one or higher. All of the PBS-treated mice had disease incidence with disease scores of higher 
than one, and 80% of the PLP-treated mice had the disease. The lowest disease incidences were 
recorded for the PLP-BPI-treated (66% with scores >1) and PLP-PEG-B7AP-treated (50% with 
scores > 1) mice.   
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3.3.2. Splenocyte cytokine production. To better understand the balance between 
inflammatory and regulatory cells in animals treated with PLP-PEG-B7AP, splenocytes were 
isolated from both PLP-PEG-B7AP- and PBS-treated mice on days 15 and 30. The types and 
levels of cytokines secreted by splenocytes provide evidence for the presence of certain types of 
immune cells upon treatment with the peptide. Although this method will not indicate the 
concentration of cytokines in systemic circulation, it will provide an idea of relative levels of 
proliferation of inflammatory and regulatory cells. With an inflammatory response, we expect a 
greater production of pro-inflammatory cytokines (IL-6, IL-17 and IFN-γ).  If there were an 
activation of regulatory and suppressor immune response, there would be a greater concentration 
of regulatory cytokines (IL-2, IL-10) and suppressor cytokines (IL-5 and IL-4) than in the 
normal condition. 
The progression of EAE is thought to be due primarily to activation and proliferation of TH17 
and TH1 cells. The BPI molecule is hypothesized to induce T-cell anergy and shift the immune 
system from inflammatory to regulatory/suppressor responses.  At day 15 there was no statistical 
difference in production of inflammatory cytokine IL-6, and only a slight difference in 
production of inflammatory cytokine IL-17 between PBS and PLP-PEG-B7AP treated groups 
P<0.001(n=3) (Figure 3.4).  Interestingly only suppression of inflammatory cytokine IFN-γ is 
observed in the PLP-PEG-B7AP group in comparison to PBS P<0.001 (n=3).  Regulatory 
cytokine IL-2 was produce at similar levels in both PLP-PEG-B7AP and PBS treated groups 
P<0.001 (n=3) (Figure3.5).  However suppressor cytokine IL-5 was produced at higher levels in 
PLP-B7AP treated groups then PBS.  While decreased production of regulatory cytokine IL-10 
and suppressor cytokine IL-4 were observed in PLP-PEG-B7AP treated groups compared to PBS 
P<0.001 (n=3) (Figure 3.5).   
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At day 30, it is clear that PLP-PEG-B7AP suppresses the production of inflammatory 
cytokines IFN-γ, IL-17, and IL-6 P<0.001 (n=3) (Figure 3.6). In contrast, the regulatory 
cytokines (IL-2, IL-10) and suppressor cytokine (IL-4) were lower in PLP-PEG-B7AP-treated 
mice than in PBS-treated mice while there was no difference in IL-5 production between the 
PLP-PEG-B7AP- and PBS-treated mice P<0.001 (n=3) (Figure 3.7). 
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Figure  3.4. Day15 Cytokine Inflammatory Cytokine Analysis.  Concentrations of pro-
inflammatory cytokines (IFN-γ, IL-17, and IL-6) in cell culture supernatants from mice 
sacrificed on day 15.  Splenocytes were isolated from the spleens of EAE mice treated with 
either PBS or PLP-PEG-B7AP on days –11, –8, and –5.  The pooled splenocytes (n = 3) were 
stimulated in vitro with PLP139-151, and the supernatants were isolated 72 h later for cytokine 
analysis. (p<0.001) * indicates significant difference. 
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Figure 3.5. Day 15 regulatory cytokine analysis. Concentrations of 
regulatory/suppressor cytokines (IL-2, IL-4, IL-5, and IL-10) from the cell culture 
supernatants of splenocytes on day 15.  Splenocytes were isolated from the spleens of 
EAE mice treated with either PBS or PLP-PEG-B7AP on days –11, –8, and –5.  The 
pooled splenocytes (n = 3) were stimulated in vitro with PLP139-151, and supernatants 
were isolated 72 h later for cytokine analysis. (p<0.001) * indicates significant difference. 
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Figure  3.6.    Day 30 inflammatory cytokine analysis. Concentrations of pro-inflammatory 
cytokines (IFN-γ, IL-17, and IL-6) in cell culture supernatants from mice sacrificed on day 30.  
Splenocytes were isolated from the spleens of EAE mice treated with either PBS or PLP-PEG-
B7AP on days –11, –8, and –5.  The pooled splenocytes (n = 3) were stimulated in vitro with 
PLP139-151, and the supernatants were isolated 72 h later for cytokine analysis. (p<0.001) * 
indicates significant difference. 
56 
 
  
 
Figure 3.7. Day 30 regulatory cytokine analysis. Concentrations of 
regulatory/suppressor cytokines (IL-2, IL-4, IL-5, and IL-10) from the cell culture 
supernatants of splenocytes on day 30.  Splenocytes were isolated from the spleens of 
EAE mice treated with either PBS or PLP-PEG-B7AP on days –11, –8, and –5.  The 
pooled splenocytes (n = 3) were stimulated in vitro with PLP139-151, and supernatants 
were isolated 72 h later for cytokine analysis. (p<0.001) * indicates significant difference. 
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3.4. Discussion 
Peptide-based treatments for EAE have been used by Ishioka et al. to suppress EAE in mice 
[26]. Peptide antagonists of T-cell receptors (TCR) have been shown to significantly suppress 
and inactivate autoreactive T cells in EAE, presumably by blocking the signal-1 connection of 
MHC-II complex with the TCR. Although it is antigenic-specific, such a therapy may not be 
very efficient because it involves only one of the two important signals of T-cell activation. In an 
effort to create a more specific and efficent immuno-suppressive therapy, our group has 
developed bifunctional peptide inhibitor (BPI) molecules that have been shown to effectively 
suppress EAE [27, 28], type-1 diabetes (T1D) [29], and rheumatoid arthritis (RA).  BPI 
treatments have been shown to be consistently more effective the corresponding treatment with 
parent antigenic peptide alone. This is due to the fact that BPI modulates both signal-1 and 
signal-2 during T-cell activation while the parent antigenic peptide modulates only signal-1 
during the formation of the immunological synapse at the interface between T cells and APC.  
The proposed mechanism of action of BPI molecules is that it can simultaneously modulate both 
signal-1 (MHC-II/TCR) and signal-2 (ICAM-1/LFA-1 or CD28/B7), leading to specific 
suppression of EAE [2].  Previously, the BPI molecule PLP-B7AP showed significant 
suppression of disease in EAE mice when treated on days 4, 7, and 10 after induction of disease 
[Unpublished data]. 
In this study, the efficacy of PLP-PEG-B7AP to suppress EAE in “vaccine-like” injections 
was evaluated by administering the molecule on days 11, 8, and 5 before induction of the disease 
on day 0. Disease scores, incidence of disease, and changes in body weight were monitored from 
day 0 to day 30. A clear difference in disease scores can be observed in PLP-PEG-B7AP- and 
PLP-BPI-treated groups compared to the negative control group (PBS) (Figure 3.1). The PLP-
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PEG-B7AP-treated group showed the lowest disease scores compared to other treated groups.  
This difference also correlates with the incidence of disease in treated mice (Figure 3.3).  Half of 
the mice treated with PLP-PEG-B7AP were considered to be without disease incidence with 
disease scores of less than one while all of the PBS-treated mice developed disease scores of 1 or 
higher. It was difficult to compare the body weights between PBS- and PLP-PEG-B7AP-treated 
mice for the entire study (Figure 3.2). This is due to the lack of a sufficient number of PBS-
treated animals for body weight measurements because some mice in the PBS-treated group 
developed very severe disease and had to be euthanized.  This can explain why there is little 
difference in changes in body weight of mice between control and PLP and PLP-BPI groups on 
days 11, 12, and 13, when the disease was very severe.  In other words, the body weights from 
animals with severe disease are not represented. However a clear difference in change in body 
weight can be observed between PBS and PLP-PEG-B7AP treated mice.  
Splenocytes were also isolated and analyzed for production of cytokines to elucidate the type 
of T cells were generated during the disease on day 15 and day 30.  Their seems to be no large 
differences in generation of regulatory and suppressor cytokines in PBS and PLP-PEG-B7AP 
groups, except in the production of IL-10 (Figure 3.4.).  This suggests a limited effect of PLP-
PEG-B7AP on the generation of regulatory and suppressor cytokines in the first appearance of 
disease on day 15.  Also on day 15, inflammatory cytokines are at or near the same levels in PBS 
and PLP-PEG-B7AP treated groups, with the exception of IFN-γ (Figure 3.5.).  IFN-γ is 
produced at far lower levels in PLP-PEG-B7AP treated mice than PBS.  This suggest that PLP-
PEG-B7AP is suppressing production of IFN-γ in the first appearance of disease on day 15.  
Contrastingly on day 30 all inflammatory cytokines tested (IL-17, IL-6, and IFN-γ) were 
produced at higher levels in PBS-treated groups than in PLP-PEG-B7AP-treated groups (figure 
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3.6.). This suggests that PLP-PEG-B7AP can lower the proliferation of inflammatory TH1 and 
TH17 cells on day 30. Previously, treatment of EAE mice with PLP-B7AP on days 4, 7, and 10 
also lowered the production of IL-17 observed on days 15 and 30; the production of IL-6 was 
lower on day 15 but not on day 30 in PLP-B7AP-treated compared to PBS-treated animals. 
Interestingly, production of IL-10, IL-2, and IL-4 on day 30 was at lower levels in PLP-PEG-
B7AP-treated compared to PBS-treated groups while there was no change in IL-5 production 
(Figure 3.7.). In contrast, PLP-B7AP-treated mice (days 4, 7, and 10) compared to PBS-treated 
mice had higher production of IL-4 and IL-2 on days 15 and 30 and a higher production of IL-5 
on day 30 but not day 15. The difference in cytokine production in PLP-B7AP- and PLP-PEG-
B7AP-treated mice could be due to two reasons: (1) the linkers in PLP-PEG-B7AP and PLP-
B7AP are different and (2) PLP-PEG-B7AP was injected as a “vaccine-like” administration 
while PLP-B7AP was administered as a prophylactic treatment. In the future, it will be necessary 
to perform side-by-side comparison of the efficacy and mechanisms of action of PLP-B7AP and 
PLP-PEG-B7AP.  
To get an idea about the types of cells involved in demyelination of the CNS, cell staining of 
brains from PBS- and PLP-PEG-B7AP-treated mice was evaluated. Brain samples were taken on 
day 15 and 30 after induction of disease, which is the time period of the first occurrence and 
remission of disease, respectively. No difference in demyelination and lesion appearance or 
leukocyte infiltration was apparent [data not shown]. It is possible that on day 30 the animals 
were still in remission; typically, the disease relapse with high severity is after day 35. Perhaps it 
would be better to observe leukocyte infiltration to the brain during the relapse stage. 
Furthermore, infiltration of T cells would be better observed in the spinal cord than in the brain.  
It has been shown by Cross et al. that myelin reactive T cells infiltrate the spinal cord before 
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permeating the brain [30].  In the future, we will evaluate the infiltration of T cells into the spinal 
cord instead of the brain in both PLP-PEG-B7AP-treated and PBS-treated groups. 
In conclusion, PLP-PEG-B7AP has been shown to effectively suppress EAE when delivered 
in a “vaccine-like” manner compared to PLP-BPI, PLP, and PBS. PLP-PEG-B7AP suppresses 
the production of inflammatory cytokines IL-17 and IFN-γ, suggesting that it also suppresses the 
proliferation of inflammatory TH17 and TH1 cells. Further studies will need to be done to 
understand the mechanism of the PLP-PEG-B7AP molecule and its effect on T-cell trafficking 
into the CNS and subsequent demyelination.  
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Conclusion and Future Directions 
In this study, the novel MOG-PEG-IDAC molecule was successfully synthesized and 
characterized.  Although the conjugation reaction to make the MOG-PEG-IDAC molecule is still 
inefficient, the yield of the reaction is better than that of MOG-IDAC. Because MOG-PEG-
IDAC can be sufficiently produced, its efficacy is currently being evaluated. Future plans 
include: (a) evaluating different conditions for the conjugation reaction to improve the yield of 
MOG-PEG-IDAC, (b) determining the efficacy of MOG-PEG-IDAC as a vaccine-like treatment, 
(c) conjugating both MOG and PLP peptides simultaneously to the I-domain to produce PLP-
MOG-IDAC, and (d) determining the efficacy of PLP-MOG-IDAC in PLP- and MOG-
stimulated EAE.  
PLP-PEG-B7AP was found to be effective in suppressing EAE as vaccine-like treatment. 
This molecule suppresses inflammatory cytokine production from isolated splenocytes compared 
to those from PBS-treated mice. However, lower levels of regulatory/suppressor cytokines (i.e., 
IL-10, IL-4) were found in PLP-PEG-B7AP-treated mice compared to PBS-treated mice during 
first appearance of disease day 15 and remission on day 30. This is in contrast to PLP-B7AP-
treated animals, which showed higher levels of regulatory cytokines compared to PBS-treated 
animals. The difference between cytokines produced by PLP-PEG-B7AP and PLP-B7AP could 
be due to the vaccine-like administration of PLP-PEG-B7AP compared to prophylactic treatment 
with PLP-B7A. Secondly, the presence of PEG groups in PLP-PEG-B7AP may alter its 
mechanism of action compared to that of PLP-B7AP. Finally, further analysis of regulatory T 
cells will be carried out by detecting CTLA-4 and FOXp3 as marker molecules on T cells.  
Currently, there is an ongoing study to evaluate the effect of MOG-PEG-B7AP in suppressing 
MOG-stimulated EAE in mice.  If suppression of EAE is demonstrated, multiantigen BPI (i.e., 
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MOG-PLP-B7AP) with a B7AP peptide connected to the MOG and PLP peptides will be 
synthesized and evaluated for suppressing MOG- and PLP-stimulated EAE. This may allow the 
MOG-PLP-B7AP to prevent antigenic spreading in MS in the future. 
 
 
 
 
 
